Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Endocrinology, Diabetes & Metabolism · 2026-11 · 9 (6)
DOI: 10.1002/edm2.70397 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 15.11.2026. Verfasst von Ahmed Adel Mohamed und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Zagazig University, Zagazig, Egypt. Hauptthemen laut MEDLINE: Metformin, Sodium-Glucose Transporter 2 Inhibitors, Polycystic Ovary Syndrome, Hypoglycemic Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Polycystic ovary syndrome (PCOS), recently redefined as polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder of reproductive‐age women. Metformin remains first‐line therapy, whereas sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have emerged for their cardiometabolic effects. This study compared SGLT2 inhibitors, alone or with metformin, versus metformin alone in PMOS.
Methods
We performed a PRISMA‐guided systematic review and meta‐analysis of randomized controlled trials from PubMed, Scopus, Web of Science, Cochrane CENTRAL and Embase. Two reviewers independently screened, extracted data, assessed risk of bias (Cochrane RoB 2) and rated certainty using GRADE. Continuous outcomes were pooled as mean differences (MD) with 95% confidence intervals (CI) under a random‐effects model; heterogeneity was assessed with I 2 .
Results
Five trials (292 women) were included. SGLT2 inhibitors did not differ significantly from metformin in body weight (MD = −2.06 kg; 95% CI −5.79 to 1.68) or BMI (MD = −0.34 kg/m 2 ; 95% CI −0.78 to 0.10), or most hormonal, glycemic and anthropometric outcomes. However, they significantly reduced triglycerides (MD = −0.21 mmol/L; 95% CI −0.38 to −0.05) and diastolic blood pressure (MD = −1.79 mmHg; 95% CI −2.57 to −1.01), with a small increase in systolic blood pressure (MD = 0.97 mmHg; 95% CI 0.11–1.83). Certainty of evidence ranged from low to high.
Conclusion
SGLT2 inhibitors, alone or with metformin, did not differ significantly from metformin across most metabolic and endocrine outcomes, with modest benefits on triglycerides and diastolic blood pressure. Metformin remains first‐line therapy; SGLT2 inhibitors may be considered in selected patients pending larger trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Zagazig University, Zagazig, Egypt.
- Faculty of Medicine, Galala University, Suez, Egypt.
- Faculty of Medicine, Minia University, Minia, Egypt.
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, The University of Jordan, Amman, Jordan.
- Faculty of Medicine, Cairo University, Cairo, Egypt.
ORCID-Profile: Ahmed Adel Mohamed, Moaz Feteih, Mark Makar Kadies, Ahmed Elsayed Elsayed Ibrahim, Osama M Aldeeb, Abdelrahman M Aldeeb, Mohammed Dibas
Zitieren
APA
Mohamed, A. A., Feteih, M., Ahmed, M. E., Kadies, M. M., Ibrahim, A. E. E., Ibrahim, M., Abusalem, Y. M., Aldeeb, O. M., Aldeeb, A. M., Shekho, M., & Dibas, M. (2026). Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism, 9(6). https://doi.org/10.1002/edm2.70397
Vancouver
Mohamed AA, Feteih M, Ahmed ME, Kadies MM, Ibrahim AEE, Ibrahim M, et al. Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026;9(6). doi:10.1002/edm2.70397
BibTeX
@article{Mohamed2026,
author = {Mohamed, Ahmed Adel and Feteih, Moaz and Ahmed, Mostafa Elsayed and Kadies, Mark Makar and Ibrahim, Ahmed Elsayed Elsayed and Ibrahim, Menna and Abusalem, Yaser M and Aldeeb, Osama M and Aldeeb, Abdelrahman M and Shekho, Mohammad and Dibas, Mohammed},
title = {Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {6},
doi = {10.1002/edm2.70397}
}
EUVIMED